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Introduction
One of the major challenges in the management of juve-
nile dermatomyositis (JDM) is to accurately assess disease
activity in order to optimize therapeutic strategies.
Whole-body(WB)-MRI enables a reliable analysis of the
site (skeletal muscle, subcutaneous tissue, myofascia) and
magnitude of inflammatory process throughout the
entire body. By providing an accurate estimation of the
total disease activity load, this technique could be useful
to tailor treatment according to disease severity.
Objectives
To explore the potential value of WB-MRI in predicting
treatment efficacy in JDM.
Methods
WB-MRI was performed on a 1.5 T MRI scanner (using
STIR sequences) to all consecutive JDM patients with
disease duration ≤ 2 months, seen at the study Depart-
ment between March 2010 and February 2013. Muscle
signal abnormalities and subcutaneous tissue/myofascial
involvement were assessed using a recently validated
WB-MRI scoring system. Treatment efficacy was
assessed at 3-months follow-up visit using the PRINTO
criteria for the evaluation of response to therapy in JDM.
Results
21 patients (9 boys, 12 girls, median age 6,6 years) were
included. Four patients were treated with prednisone
alone, while the others received prednisone in different
combinations with methotrexate (N = 15) or cyclospor-
ine (N = 2). Eleven patients (52.4%) met the PRINTO
criteria for improvement at 3-months follow-up visit.
WB-MRI muscular score was significantly higher in
non-responders (median value: 61.2; IQR 53.5-65.5)
compared to the responders (34.5; IQR 18-55 p =
0.001). A WB-MRI muscle score >57 was predictive of a
poor response to treatment, as evaluated by ROC curve
analysis (AUC:0,9; IC95%: 0,70-0,99; sensitivity: 100%,
specificity: 70% + LR: 3,33 - LR: 0,00). Non-responders
showed also a significant higher myofascial score (med-
ian value 1.5; IQR 0-3.5) compared to the improved
patients (0; IQR 0-1.5 p = 0.04); no significant difference
in subcutaneous involvement was found between
responders (0.5; IQR 0-1.5) and non-responders (2.5;
IQR 0.5-7; p = 0.08). Seven out of 8 patients (87.5%)
with diffuse and homogeneous pattern of distribution of
muscle inflammation were not improved at 3 months
follow-up visit; viceversa 10 out of 13 patients with the
typical patchy distribution of muscle signal abnormal-
ities were improved (p = 0.02).
Conclusion
High WB-MRI muscular and myofascial scores and the
diffuse and homogeneous pattern of muscle inflamma-
tion were associated with a more severe disease course.
WB-MRI represents a promising tool to identify patients
who could benefit from a more aggressive therapeutic
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